Becton, Dickinson and Company $BDX Shares Acquired by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. increased its stake in Becton, Dickinson and Company by 3.7% in Q1, making it the firm’s 5th largest position, consisting of approximately 1.9% of their investment portfolio.
• Analysts have mixed opinions on Becton, Dickinson, with Citigroup lowering their price target to $185, while Morgan Stanley raised it to $197, reflecting varying outlooks on stock performance.
• Becton, Dickinson recently declared a quarterly dividend of $1.04 per share, with a yield of 2.1%, scheduled to be paid on September 30th to investors of record on September 8th.

T. Rowe Price Investment Management Inc. boosted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,575,351 shares of the medical instruments supplier's stock after acquiring an additional 448,644 shares during the period. Becton, Dickinson and Company accounts for about 1.9% of T. Rowe Price Investment Management Inc.'s investment portfolio, making the stock its 5th largest position. T. Rowe Price Investment Management Inc. owned about 4.39% of Becton, Dickinson and Company worth $2,880,510,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $27,000. Alpine Bank Wealth Management acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $29,000. REAP Financial Group LLC grew its stake in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares during the last quarter. Cornerstone Planning Group LLC boosted its stake in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 99 shares during the last quarter. Finally, Nexus Investment Management ULC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $34,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Citigroup cut shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their price target for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target on the stock. in a research note on Friday, May 2nd. Barclays decreased their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Four analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $211.44.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 863 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the sale, the director owned 23,143 shares of the company's stock, valued at $4,450,398.90. This represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Shan sold 1,166 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. The trade was a 20.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,214 shares of company stock valued at $579,206 over the last 90 days. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Up 1.5%

NYSE BDX traded up $2.8730 during mid-day trading on Friday, hitting $199.5030. The company's stock had a trading volume of 1,619,788 shares, compared to its average volume of 2,720,196. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The stock's fifty day simple moving average is $180.65 and its two-hundred day simple moving average is $195.60. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a market capitalization of $57.18 billion, a P/E ratio of 35.88, a price-to-earnings-growth ratio of 1.47 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the prior year, the business earned $3.50 earnings per share. The business's quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.